A Phase 2 Study Of Prostate Specific Antigen-3 (PSA-3) (NSC # 694155) With Montanide (NSC #675756) Vaccination In Patients With Prostate Cancer Recurrent
OBJECTIVES: I. Determine the effect of PSA-3 peptide vaccine emulsified in Montanide ISA-51
on PSA levels in patients with recurrent prostate cancer. II. Determine the toxicity of this
regimen in these patients. III. Determine whether the T lymphocyte immune response to PSA-3
and HLA-A2 antigen-presenting cells that endogenously produce PSA is increased in patients
treated with this regimen. IV. Determine the duration of the PSA and/or immune responses in
patients treated with this regimen. V. Correlate immune and PSA responses in patients
treated with this regimen. VI. Determine the efficacy of a second (boost) vaccination with
this regimen in patients with a PSA or immune response.
OUTLINE: This is a multicenter study. Patients receive PSA-3 peptide vaccine emulsified in
Montanide ISA-51 subcutaneously in 2 sites on days 1, 8, 15, and 22 in the absence of
unacceptable toxicity. Patients who show an immune or prostate specific antigen (PSA)
response are followed until disease progression, defined as a diminution or disappearance of
an immune response or 2 consecutive increases in PSA over the nadir. Patients are eligible
for a second series of injections at the time of progression.
PROJECTED ACCRUAL: A total of 14-44 patients will be accrued for this study within 12-18
months.
Interventional
Primary Purpose: Treatment
Nancy A. Dawson, MD
Study Chair
University of Maryland Greenebaum Cancer Center
United States: Federal Government
CDR0000069181
NCT00030602
Name | Location |
---|